Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.57 |
| ▸ | CACNA1B | Q00975 | 9/20 | 0.51 |
| ▸ | CACNA1H | O95180 | 7/20 | 0.51 |
| ▸ | PLA2G7 | Q13093 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6176083 | 0.90 | CACNA1B (0.57) | UTS2RCACNA1BCACNA1H | |
| SCHEMBL6179473 | 0.87 | CACNA1B (0.54) | UTS2RCACNA1BCACNA1H | |
| SCHEMBL6177731 | 0.87 | CACNA1B (0.65) | UTS2RCACNA1BCACNA1H | |
| SCHEMBL6176698 | 0.84 | MAPT (0.57) | UTS2RCACNA1BCACNA1HPLA2G7MAPT | |
| SCHEMBL6178070 | 0.84 | CACNA1B (0.52) | CACNA1BCACNA1HPLA2G7MAPT | |
| SCHEMBL6186717 | 0.84 | CACNA1B (0.54) | UTS2RCACNA1BCACNA1HPLA2G7MEN1 | |
| SCHEMBL6177607 | 0.83 | CACNA1B (0.55) | UTS2RCACNA1BCACNA1HPLA2G7LMNA | |
| SCHEMBL6176052 | 0.83 | CACNA1B (0.53) | UTS2RCACNA1BCACNA1HMEN1LMNA | |
| SCHEMBL6174632 | 0.82 | CACNA1B (0.53) | UTS2RCACNA1BCACNA1HLMNAMAPT | |
| SCHEMBL6177543 | 0.81 | CACNA1B (0.59) | UTS2RCACNA1BCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399137-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-12-14 | — | — | EP | claimed |
| US-6849635-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-01 | — | — | US | claimed |
| US-20040152893-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | claimed |
| EP-1399137-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-03-24 | — | — | EP | claimed |
| WO-2002089785-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | claimed |
| EP-1399137-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-12-14 | — | — | EP | disclosed |
| US-6849635-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040152893-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| EP-1399137-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002089785-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152893-A1 | Sulfonamides | UTS2R, PRSS2, STS | UTS2R 1/4885CACNA1B 3246/4885CACNA1H 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.